FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
FLT3 receptor tyrosine kinase is expressed on lymphoid and myeloid progenitors in the hematopoietic system. Activating mutations in FLT3 have been identified in approximately 30% of patients with acute myelogenous leukemia, making it one of the most common mutations observed in this disease. Frequently, the mutation is an in-frame internal tandem duplication (ITD) in the juxtamembrane region that results in constitutive activation of FLT3, and confers interleukin-3 (IL-3)–independent growth to Ba/F3 and 32D cells. FLT3-ITD mutants were cloned from primary human leukemia samples and assayed for transformation of primary hematopoietic cells using a murine bone marrow transplantation assay. FLT3-ITDs induced an oligoclonal myeloproliferative disorder in mice, characterized by splenomegaly and leukocytosis. The myeloproliferative phenotype, which was associated with extramedullary hematopoiesis in the spleen and liver, was confirmed by histopathologic and flow cytometric analysis. The disease latency of 40 to 60 days with FLT3-ITDs contrasted with wild-type FLT3 and enhanced green fluorescent protein (EGFP) controls, which did not develop hematologic disease (> 200 days). These results demonstrate that FLT3-ITD mutant proteins are sufficient to induce a myeloproliferative disorder, but are insufficient to recapitulate the AML phenotype observed in humans. Additional mutations that impair hematopoietic differentiation may be required for the development of FLT3-ITD–associated acute myeloid leukemias. This model system should be useful to assess the contribution of additional cooperating mutations and to evaluate specific FLT3 inhibitors in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., & Misawa, S. (1996) · PubMed · Cited by 1,162
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
Yamamoto, Y. (2001) · Blood · doi:10.1182/blood.v97.8.2434 · Cited by 1,150
McKenna, H. J., Stocking, K. L., Miller, R. E., Brasel, K., De Smedt, T., Maraskovsky, E., Maliszewski, C. R., Lynch, D. H., Smith, J., Pulendran, B., et al. (2000) · Blood · doi:10.1182/blood.v95.11.3489 · Cited by 932
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., Schlessinger, J., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90689-n · Cited by 659
Versatile retroviral vectors for potential use in gene therapy.
Hawley, R. G., Lieu, F. H., Fong, A. Z. C., & Hawley, T. S. (1994) · PubMed · Cited by 652
Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Müller, C., Grüning, W., Kratz-Albers, K., Serve, S., Steur, C., et al. (2000) · Blood · doi:10.1182/blood.v96.12.3907 · Cited by 606
Mackarehtschian, K., Hardin, J. D., Moore, K. A., Boast, S., Goff, S. P., & Lemischka, I. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90167-1 · Cited by 580
Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., & Naoe, T. (2000) · Oncogene · doi:10.1038/sj.onc.1203354 · Cited by 579
Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., & Druker, B. J. (1997) · Blood · doi:10.1182/blood.v90.12.4947 · Cited by 554
Self-citationMeshinchi, S., Woods, W. G., Stirewalt, D. L., Sweetser, D. A., Buckley, J. D., Tjoa, T. K., Bernstein, I. D., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.1.89 · Cited by 518
Matthews, W., Jordan, C. T., Gavin, M., Jenkins, N. A., Copeland, N. G., & Lemischka, I. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.20.9026 · Cited by 501
Peeters, P., Raynaud, S. D., Cools, J., Wlodarska, I., Grosgeorge, J., Philip, P., Monpoux, F., Van Rompaey, L., Baens, M., Van den Berghe, H., et al. (1997) · Blood · doi:10.1182/blood.v90.7.2535 · Cited by 491
Ilaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
Yokota, S., Kiyoi, H., Nakao, M., Iwai, T., Misawa, S., Okuda, T., Sonoda, Y., Abe, T., Kahsima, K., Matsuo, Y., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400812 · Cited by 455
Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H., & Naoe, T. (1998) · Leukemia · doi:10.1038/sj.leu.2401130 · Cited by 453
Okuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C.-J., van Deursen, J. M. A., Harada, H., & Downing, J. R. (1998) · Blood · doi:10.1182/blood.v91.9.3134 · Cited by 372
Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G., & Ley, T. J. (1997) · Blood · doi:10.1182/blood.v89.2.376 · Cited by 352
Acute leukemia with promyelocytic features in PML/RARα transgenic mice
He, L.-Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V., Cattoretti, G., & Pandolfi, P. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5302 · Cited by 339
Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia
Golub, T. R., Goga, A., Barker, G. F., Afar, D. E. H., McLaughlin, J., Bohlander, S. K., Rowley, J. D., Witte, O. N., & Gilliland, D. G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4107 · Cited by 324
Self-citationFLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., Gari, M. A., Peake, I. R., Rees, D. C., Vandenberghe, E. A., Winship, P. R., & Reilly, J. T. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02317.x · Cited by 310
Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303
Self-citationCastilla, L. H., Garrett, L., Adya, N., Orlic, D., Dutra, A., Anderson, S., Owens, J., Eckhaus, M., Bodine, D., & Liu, P. P. (1999) · Nature Genetics · doi:10.1038/13776 · Cited by 302
Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family.
Rosnet, O., Marchetto, S., deLapeyrière, O., & Birnbaum, D. (1991) · PubMed · Cited by 287
Carroll, M., Tomasson, M. H., Barker, G. F., Golub, T. R., & Gilliland, D. G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14845 · Cited by 268
Self-citationHematologic effects of flt3 ligand in vivo in mice
Brasel, K., McKenna, H., Morrissey, P., Charrier, K., Morris, A., Lee, C., Williams, D., & Lyman, S. (1996) · Blood · doi:10.1182/blood.v88.6.2004.bloodjournal8862004 · Cited by 260
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model
Rhoades, K. L., Hetherington, C. J., Harakawa, N., Yergeau, D. A., Zhou, L., Liu, L.-Q., Little, M.-T., Tenen, D. G., & Zhang, D.-E. (2000) · Blood · doi:10.1182/blood.v96.6.2108 · Cited by 257
The novel activation of ABL by fusion to an ets-related gene, TEL.
Papadopoulos, P., Ridge, S. A., Boucher, C. A., Stocking, C., & Wiedemann, L. M. (1995) · PubMed · Cited by 256
Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., Ross, T. S., Peeters, P., Van Rompaey, L., Van Etten, R. A., Ilaria, R., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5321 · Cited by 245
Self-citationBirg, F., Courcoul, M., Rosnet, O., Bardin, F., Pebusque, M., Marchetto, S., Tabilio, A., Mannoni, P., & Birnbaum, D. (1992) · Blood · doi:10.1182/blood.v80.10.2584.2584 · Cited by 226
Persons, D. A., Allay, J. A., Allay, E. R., Smeyne, R. J., Ashmun, R. A., Sorrentino, B. P., & Nienhuis, A. W. (1997) · Blood · doi:10.1182/blood.v90.5.1777 · Cited by 222
Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T., et al. (1997) · Leukemia · doi:10.1038/sj.leu.2400770 · Cited by 209
Zhang, S., Fukuda, S., Lee, Y., Hangoc, G., Cooper, S., Spolski, R., Leonard, W. J., & Broxmeyer, H. E. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.719 · Cited by 206
Tse, K.-F., Mukherjee, G., & Small, D. (2000) · Leukemia · doi:10.1038/sj.leu.2401905 · Cited by 195
Ross, T. S., Bernard, O. A., Berger, R., & Gilliland, D. G. (1998) · Blood · doi:10.1182/blood.v91.12.4419 · Cited by 186
Self-citationGille, H., Kowalski, J., Yu, L., Chen, H., Pisabarro, M. T., Davis-Smyth, T., & Ferrara, N. (2000) · The EMBO Journal · doi:10.1093/emboj/19.15.4064 · Cited by 181
Xu, F., Taki, T., Yang, H. W., Hanada, R., Hongo, T., Ohnishi, H., Kobayashi, M., Bessho, F., Yanagisawa, M., & Hayashi, Y. (1999) · British Journal of Haematology · doi:10.1111/j.1365-2141.1999.01284.x · Cited by 178
The CML-Specific P210 bcr / abl Protein, Unlike v- abl , Does Not Transform NIH/3T3 Fibroblasts
Daley, G. Q., McLaughlin, J., Witte, O. N., & Baltimore, D. (1987) · Science · doi:10.1126/science.2440107 · Cited by 172
Dosil, M., Wang, S., & Lemischka, I. R. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6572 · Cited by 172
Jacobsen, S. E., Okkenhaug, C., Myklebust, J., Veiby, O. P., & Lyman, S. D. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.4.1357 · Cited by 163
Fenski, Flesch, Serve, Mizuki, Oelmann, Kratz‐Albers, Kienast, Leo, Schwartz, Berdel, et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01831.x · Cited by 146
Rappold, I., ZIEGLER, B. L., Köhler, I., Marchetto, S., Rosnet, O., Birnbaum, D., Simmons, P. J., Zannettino, A. C. W., Hill, B. L., Neu, S., et al. (1997) · Blood · doi:10.1182/blood.v90.1.111 · Cited by 143
c-Kit and c-kit mutations in mastocytosis and other hematological diseases
Boissan, M., Féger, F., Guillosson, J., & Arock, M. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.2.135 · Cited by 137
Zeigler, F., Bennett, B., Jordan, C. T., Spencer, S., Baumhueter, S., Carroll, K., Hooley, J., Bauer, K., & Matthews, W. (1994) · Blood · doi:10.1182/blood.v84.8.2422.2422 · Cited by 137
Zhang, S., Mantel, C., & Broxmeyer, H. E. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.65.3.372 · Cited by 133
Schwaller, J., Anastasiadou, E., Cain, D., Kutok, J. L., Wojiski, S. A., Williams, I. R., Starza, R. L., Crescenzi, B., Sternberg, D., Andreasson, P., et al. (2001) · Blood · doi:10.1182/blood.v97.12.3910 · Cited by 130
Self-citationPendergast, A. M., Gishizky, M. L., Havlik, M. H., & Witte, O. N. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1728-1736.1993 · Cited by 122
Hematopoietic receptors of class III receptor-type tyrosine kinases.
Rosnet, O., & Birnbaum, D. (1993) · PubMed · Cited by 118
Tomasson, M. H., Sternberg, D., Williams, I. R., Carroll, M. P., Cain, D., Aster, J. C., Ilaria, R. L., Etten, R. A. V., & Gilliland, D. G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8902 · Cited by 111
Self-citationExpression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines.
Meierhoff, G., Dehmel, U., Gruss, H. J., Rosnet, O., Birnbaum, D., Quentmeier, H., Dirks, W. G., & Drexler, H. G. (1995) · PubMed · Cited by 110
Liu, Q., Schwaller, J., Kutok, J. L., Cain, D., Aster, J. C., Williams, I. R., & Gilliland, D. G. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1827 · Cited by 110
Self-citationMolineux, G., McCrea, C., Yan, X. Q., Kerzic, P. J., & McNiece, I. (1997) · Blood · doi:10.1182/blood.v89.11.3998 · Cited by 108
Tomasson, M. H., Williams, I. R., Hasserjian, R. P., Udomsakdi, C., McGrath, S. M., Schwaller, J., Druker, B. J., & Gilliland, D. G. (1999) · Blood · doi:10.1182/blood.v93.5.1707 · Cited by 108
Self-citationFLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver
Muench, M. O., Roncarolo, M., Menon, S., Xu, Y., Kastelein, R., Zurawski, S., Hannum, C., Culpepper, J., Lee, F., & Namikawa, R. (1995) · Blood · doi:10.1182/blood.v85.4.963.bloodjournal854963 · Cited by 94
Maroc, N., Rottapel, R. K., Rosnet, O., Marchetto, S., Lavezzi, C., Mannoni, P., Birnbaum, D., & Dubreuil, P. C. (1993) · PubMed · Cited by 92
FLT3: Receptor and Ligand. Biology and Potential Clinical Application
Shurin, M. R. (1998) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00035-x · Cited by 84
Matulonis, U. A., Salgia, R., Okuda, K., Druker, B. J., & Griffin, J. D. (1993) · PubMed · Cited by 83
In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor
Zhao, M., Kiyoi, H., Yamamoto, Y., Ito, M. A., Towatari, M., Ōmura, S., Kitamura, T., Ueda, R., Saito, H., & Naoe, T. (2000) · Leukemia · doi:10.1038/sj.leu.2401680 · Cited by 79
Piacibello, W., Fubini, L., Sanavio, F., Brizzi, M., Severino, A., Garetto, L., Stacchini, A., Pegoraro, L., & Aglietta, M. (1995) · Blood · doi:10.1182/blood.v86.11.4105.bloodjournal86114105 · Cited by 78
Rottapel, R. K., Turck, C. W., Castéran, N., Liu, X., Birnbaum, D., Pawson, T. J., & Dubreuil, P. C. (1994) · PubMed · Cited by 73
TEL/PDGFβR fusion protein activates STAT1 and STAT5
Wilbanks, A. M., Mahajan, S., Frank, D. A., Druker, B. J., Gilliland, D. G., & Carroll, M. P. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00138-7 · Cited by 70
Self-citationRoss, T. S., & Gilliland, D. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.32.22328 · Cited by 68
Self-citationJuan, T., McNiece, I., Van, G., Lacey, D. L., Hartley, C. A., McElroy, P. L., Sun, Y. S., Argento, J., Hill, D., Yan, X.-Q., et al. (1997) · Blood · doi:10.1182/blood.v90.1.76 · Cited by 31
Tomasson, M. H., Williams, I. R., Li, S., Kutok, J. L., Cain, D., Gillessen, S., Dranoff, G., Etten, R. A. V., & Gilliland, D. G. (2001) · Blood · doi:10.1182/blood.v97.5.1435 · Cited by 19
Self-citationMolecular abnormalities in myeloid leukemias and myelodysplastic syndromes
Sawyers, C. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00109-x · Cited by 13
Cited by
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
The roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558
Self-citationMPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
Self-citationThe role of FLT3 in haematopoietic malignancies
Stirewalt, D. L., & Radich, J. P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1169 · Cited by 865
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Metadata
- Authors
- Kelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-01-01
- Volume
- 99
- Issue
- 1
- Pages
- 310-318
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2086626683
- Cited by
- 487
- References
- 71
- FWCI
- 20.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.